Neurotech International Ltd has released a press release.
Appendix 4E & Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurotech International Ltd. on 6ix
Story so far
Earlier from Neurotech International
- First Patient Treated in Rett Syndrome Clinical Trial
- NTI Receives HREC Approval for Rett Syndrome Clinical Trial
- NTI Granted 2 Year Extension of Treatment for ASD Patients
- NTI granted HREC Approval for PANDAS/PANS Trial Extension
- NTI Completes Recruitment in PANDAS/PANS Clinical Trial
Later from Neurotech International
- Last Patient Completes Treatment in NTIPANS1 Clinical Trial
- Completion of Patient Recruitment in NTIRTT1 Clinical Trial
- Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint
- Neurotech Receives $3.17 Million R&D Tax Incentive Refund
- HREC Approval to Extend Phase II/III ASD Trial to Adults
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International